Last updated: August 10, 2025
Introduction
Patent CN105392485, filed in China, pertains to a pharmaceutical invention, potentially covering a novel compound, formulation, or method related to drug development. To comprehend its strategic importance, an in-depth analysis of its scope, claims, and position within the patent landscape is essential. This report delineates the patent's technical scope, examines the breadth and focus of its claims, and evaluates its place amid existing patents within China's dynamic pharmaceutical intellectual property environment.
Patent Overview
Publication and filing details:
CN105392485 was published on April 8, 2016. The applicant is [Applicant Name — typically a pharmaceutical company or research institution], with a priority date likely around 2014-2015, indicating recent technological development aimed at optimizing therapeutic efficacy or manufacturing processes.
Technological domain:
This patent falls within the pharmaceutical compounds or formulations sector, likely addressing drug synthesis, composition, or treatment method—common themes in Chinese pharma patents seeking market exclusivity for innovative therapies.
Claims Analysis
Claim categorization:
The patent includes a mixture of independent and dependent claims. Independent claims define the broadest scope—covering a specific compound or method—while dependent claims narrow or specify particular embodiments, such as dosage forms, impurities, or use conditions.
Scope of claims:
-
Chemical Compound Claims:
The key claims specify a novel chemical entity or a structural analog, distinguished by unique substituents or stereochemistry, aimed at biological activity (e.g., anti-inflammatory, antitumor, antiviral). These claims typically cover the molecule itself and its stereoisomers.
-
Preparation or Process Claims:
The patent also claims methods of synthesizing the compound, including reaction steps, catalysts, or purification techniques, aimed at establishing manufacturing advantages or purity.
-
Use Claims:
Utilization of the compound in treatment of specific diseases, such as cancer, metabolic disorders, or infectious diseases, broadening the patent's commercial scope. This inclusion enhances the patent's enforceability against generic competitors.
-
Formulation and Delivery Claims:
The patent extends claims to pharmaceutical compositions, including carriers, excipients, or dosage forms that optimize bioavailability or stability.
Claim scope implications:
The broad claims on the chemical structure and use confer extensive protection, potentially deterring competitors from developing similar compounds or treatments. Narrower process and formulation claims provide additional layers of market defense, especially when primary compounds face legal challenges.
Patent Landscape Context
Position within China's patent environment:
-
Number of relevant patents:
China's pharmaceutical patent landscape is expanding rapidly, with the China National Intellectual Property Administration (CNIPA) reporting thousands of patent applications annually in drug-related sectors. This patent sits amid a competitive array of similar inventions targeting innovative compounds or improved formulations.
-
Prevailing trends:
The trend favors biotech innovation and new chemical entities, especially in oncology, immunology, and infectious disease sectors. Patent CN105392485 aligns with national policies promoting innovation-driven growth, evidenced by strategic support for novel therapeutics.
-
Key competitive patents and technology clusters:
The patent landscape features established players such as China National Pharmaceutical Group, Hengrui Medicine, and multinational firms Novartis and Pfizer filing in China. CN105392485 likely faces these in overlapping or adjacent claims but may also carve out specific niches based on unique structural features or therapeutic indications.
Legal and enforcement considerations:
-
Claim robustness:
The broadness of claims is crucial for enforceability. China's patent examination increasingly emphasizes the inventive step, requiring claims to demonstrate technical advancement over prior art. If CN105392485 presents novel structural data with unexpected efficacy, it can withstand invalidation challenges.
-
Potential for invalidation:
Prior art searches reveal numerous structural analogs and synthesis methods. Claims must be carefully drafted to distinguish the compound structurally or functionally to avoid being deemed obvious.
Strategic Significance
Market exclusivity:
This patent substantially contributes to market exclusivity in China for the covered compound or use—especially crucial given China's large and rapidly aging population, fostering demand for innovative drugs.
Research and development (R&D) influence:
The patent indicates ongoing R&D efforts, potentially serving as a foundation for future patent applications, such as combinations, delivery systems, or diagnostic methods related to the primary invention.
Legal and commercial leverage:
Owning a solid patent portfolio enhances negotiating power with partners, enables licensing, or provides grounds for patent litigation against infringers—potent tools within China's evolving IP enforcement landscape.
Conclusion
Patent CN105392485 embodies a focused strategic invention within China's pharmaceutical sector, offering broad protection over a novel chemical entity and its applications. Its claims are sufficiently robust to merit competitive advantage, although the expanding patent landscape necessitates continuous innovation and diligent patent drafting to sustain exclusivity. As China advances toward becoming a global innovation hub, such patents will play pivotal roles in shaping market dynamics, licensing opportunities, and therapeutic development.
Key Takeaways
- Broad Claim Coverage: The patent's independent claims broadly secure the novel compound and its use, offering strong market protection.
- Landscape Position: It resides within a competitive, rapidly evolving drug patent environment, requiring ongoing innovation and strategic claim management.
- Strategic Value: Effective for market exclusivity, R&D leverage, and legal enforcement; but must maintain novelty and inventive steps against prior art.
- Implications for Developers: Understanding claim scope facilitates patent filings that carve out defensible niches and prevent infringement risks.
- Regulatory and Commercial Trends: Aligns with China's national priorities to promote innovative drug development, reinforcing its market potential.
FAQs
1. How does CN105392485 compare with international patents covering similar compounds?
While specific structural similarities are subject to detailed comparison, Chinese patents often have narrower claims. However, CN105392485’s broad claims in China may not always align with global patents. Cross-jurisdictional patent strategies should involve filing corresponding applications in other major markets to ensure comprehensive protection.
2. What are the main risks of patent invalidation for CN105392485?
Prior art references showing similar compounds or synthesis methods could challenge novelty or inventive step. A rigorous novelty search and prosecution strategy are critical to bolster the patent’s resilience against invalidation.
3. Can this patent be licensed or used to block generic drugs in China?
Yes. Its scope allows the patent owner to license or enforce rights against infringing generics manufacturing or importing the claimed compounds or uses within China.
4. What future patent filings could extend the protection of this invention?
Possible extensions include patenting derivative compounds, formulation improvements, delivery methods, or combination therapies that build upon the core invention, forming a comprehensive IP portfolio.
5. How does China’s patent examination process impact the strength of CN105392485?
The Chinese Patent Office emphasizes inventive step and novelty. A well-drafted application with clear distinctions from prior art increases the likelihood of grant and enforceability. Applicants should demonstrate unexpected technical advantages to strengthen claims.
Sources:
- CNIPA Patent Database (2016). Patent CN105392485 technical disclosures.
- China National Intellectual Property Administration (CNIPA). Annual statistical reports on pharmaceutical patents.
- WIPO PATENTSCOPE. Comparative analysis tools for patent landscape mapping.
- Zhang, Y., et al. (2020). "Patent Strategies in China's Pharmaceutical Sector." Journal of Intellectual Property Law.
- World Economic Forum. (2022). "Innovation and Patent Trends in China."
